AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04221776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group toilet training in daycare
Description: During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
Study NCT04221776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual toilet training at home
Description: Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
Study NCT03218800 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes.
Study NCT03218800 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes.
Study NCT00814060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study NCT01809639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Study NCT01809639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard placebo
Study NCT03288233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath carbon monoxide measurement
Description: Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
Study NCT04325841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine autologous anti-CD19 chimeric antigen receptor T cells
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
Study NCT03675009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Programming
Description: Green Cleaning educational programming to day care staff.
Study NCT00978757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine: 0.25 mg/kg, intravenously, one dose.
Study NCT00978757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study NCT02883257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
Study NCT04228133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT)
Description: A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
Study NCT04228133 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification (ABM)
Description: A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
Study NCT00845091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: moderate-intensity, low-impact, supervised, aerobic exercise
Study NCT00845091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Healthy Education
Description: Educational topics related to heart health (e.g., nutrition, smoking, sleep)
Study NCT01707407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
Study NCT01707407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: 50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
Study NCT01707407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11
Study NCT01175941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: 10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
Study NCT01175941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched placebo - administered as a 2 g suppository, once daily for 7 days
Study NCT01390259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Open-Loop
Description: This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
Study NCT01390259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop
Description: In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
Study NCT04385563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B211
Description: Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
Study NCT04385563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
Study NCT04437121 — intervention group
Intervention type: OTHER
Intervention: Online Survey about Dietary and Lifestyle Habits
Description: An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections.
Study NCT03665519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk
Description: The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
Study NCT03665519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid treatment will be given for 3 months.
Study NCT03665519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid treatment will be given for 3 months.
Study NCT02117557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic surgery
Study NCT02117557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Study NCT01142804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group
Description: Walking programs with various levels of support will be administered to determine which one is most effective.
Study NCT03069729 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
Study NCT03712085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal acupuncture
Description: Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
Study NCT03712085 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham abdominal acupuncture
Description: Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
Study NCT04122651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'Off the shelf' toric lens
Description: 'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
Study NCT04122651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Toric lens
Description: Fully targeted toric intraocular lens correction for corneal astigmatism
Study NCT00685009 — intervention group
Intervention type: DRUG
Intervention: Estrogen hormone therapy
Description: Estrogen pill daily
Study NCT00685009 — intervention group
Intervention type: DRUG
Intervention: Estrogen plus progesterone hormone therapy
Description: Estrogen plus progesterone hormone therapy pill (Prempro) daily
Study NCT00685009 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo pill daily
Study NCT03229694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer 125Mg Tablet
Description: Tracleer was administered orally at two hours before surgery and six hours after surgery.
Study NCT03229694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally at two hour before surgery and six hours after surgery.
Study NCT02270944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS Vaccine
Description: Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
Study NCT02270944 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBS Vaccine
Description: Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
Study NCT03336593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
Study NCT03336593 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: 1 dose of Trivalent Influenza Vaccine
Study NCT03523598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel + Normal Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT03523598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Gel + Potassium Nitrate Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT03523598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate Gel + Normal Toothpaste
Description: * 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT01552421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TV NOTES cholecystectomy
Description: Transvaginal NOTES cholecystectomy
Study NCT01311284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope
Description: Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
Study NCT01311284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: intubate with the macintosh laryngoscope
Study NCT04385563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
Study NCT04385563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
Study NCT01311284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath
Description: Intubate with McGrath device
Study NCT01311284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq Nasotracheal
Description: intubate with Airtraq Nasotracheal
Study NCT02603263 — intervention group
Intervention type: OTHER
Intervention: Social Norms Poster
Description: A poster containing a social norms message: Most people here choose to eat vegetables with their lunch
Study NCT00569894 — intervention group
Intervention type: BIOLOGICAL
Intervention: FLuMist
Description: One or two vaccinations with FluMist depending on prior vaccination status.
Study NCT03456882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RNS60
Description: normal saline plus oxigen in nanobubble
Study NCT03456882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNS60
Description: normal saline plus oxigen in nanobubble
Study NCT01144299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: Single intramuscular dose on Day 0
Study NCT05128708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined medial and caudal approach right hemicolectomy open and laparoscopic
Description: resection of right colon cancer by this radical approach
Study NCT02133703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet DA
Description: BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
Study NCT02133703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet DA
Description: BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
Study NCT02133703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Print DA
Description: BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
Study NCT02133703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Print DA
Description: BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
Study NCT02133703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inconclusive Results DA
Description: Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
Study NCT05673798 — intervention group
Intervention type: OTHER
Intervention: initial chemotherapy response
Description: Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
Study NCT02938715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teledermatology feedback
Description: subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
Study NCT03471624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
Study NCT01175681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischaemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
Study NCT01306929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pridopidine
Description: 45mg bid
Study NCT00985829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
Study NCT01870076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Study NCT01870076 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healing Touch, Sham
Study NCT01870076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control, Presence
Study NCT02434588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bhattacharjee ring
Description: Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery